ASH 2018 | Update on ELIANA for CAR T-cell product tisagenlecleucel in ALL

Stephan Grupp

Here, Stephan Grupp, MD, PhD, of the Children’s Hospital of Philadelphia, Philadelphia, PA, presents an update of ELIANA (NCT02435849), which investigated the now FDA-approved CD19-directed CAR T-cell product tisagenlecleucel – now with additional patients and a further 11 months follow-up since the previous report, from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

Share this video